Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

IKT
Inhibikase Therapeutics, Inc. Common Stock
stock NASDAQ

At Close
Jul 13, 2026 3:59:50 PM EDT
1.96USD-3.922%(-0.08)356,736
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jul 14, 2026 8:37:30 AM EDT
2.10USD+7.143%(+0.14)65,060
After-hours
Jul 10, 2026 4:16:30 PM EDT
2.00USD-1.478%(-0.03)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 11, 2022
12:08PM EST  FiveT Investment Management Reports In 13D Filing A 6.03% Stake In Inhibikase Therapeutics   Benzinga
Jan 5, 2022
08:33AM EST  Inhibikase Therapeutics Highlights 2022 Pipeline Goals And Milestones   Benzinga
Nov 29, 2021
08:11AM EST  IKT Highlights Mechanism Of Disease& Potential Of Oral C-Abl Kinase Inhibitor Therapy For Parkinson's Disease Treatment   RTTNews
08:07AM EST  Inhibikase Therapeutics Announces Publication Highlighting Mechanism Of Disease And Potential Of Oral c-Abl Kinase Inhibitor Therapy For Treatment Of Parkinson's Disease   Benzinga
08:05AM EST  and the Potential of Oral c-Abl Kinase Inhibitor Therapy for the Treatment of Parkinson's Disease   PR Newswire
Nov 15, 2021
06:52PM EST  Inhibikase Therapeutics Q3 EPS $(0.18) Down From $(0.08) YoY, Sales $328.46K Up From $37.68K YoY   Benzinga
05:30PM EST  Inhibikase Therapeutics Reports Third Quarter 2021 Financial Results and   PR Newswire
Oct 27, 2021
08:05AM EDT  Inhibikase Therapeutics to Participate in Upcoming Michael J. Fox Foundation   PR Newswire
Oct 19, 2021
08:07AM EDT  Inhibikase Therapeutics Reports Dosing Of First Patient For Phase 1b Trial Of IkT-148009 For Parkinson's   Benzinga
08:05AM EDT  Inhibikase Therapeutics Announces Dosing of First Parkinson's Patient in its   PR Newswire
Oct 7, 2021
08:24AM EDT  The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results   Benzinga
Oct 4, 2021
08:11AM EDT  Inhibikase Therapeutics Announces Interim Three-month Results From Chronic Toxicology Studies Of Oral c-Abl Kinase Inhibitor, IkT-148009, In Development For Treatment Of Parkinson's Disease   Benzinga
08:05AM EDT  Toxicology Studies of its Oral c-Abl Kinase Inhibitor, IkT-148009, in Development for Treatment of Parkinson's Disease   PR Newswire
Sep 23, 2021
08:07AM EDT  Inhibikase Gets Grant From US National Institutes Of Health To Evaluate IkT-148009 For Multiple System Atrophy Treatment   RTTNews
08:06AM EDT  Inhibikase Therapeutics Reports Received ~$385K Grant From US National Institutes Of Health To Evaluate IkT-148009 For Treatment Of Multiple System Atrophy   Benzinga
08:05AM EDT  Inhibikase Therapeutics Receives Grant from U.S. National Institutes of Health   PR Newswire
Sep 7, 2021
08:01AM EDT  Inhibikase Therapeutics to Present at Upcoming H.C. Wainwright 23rd Annual   PR Newswire
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 16, 2021
04:48PM EDT  Inhibikase Therapeutics Q2 EPS $(0.22) Down From $(0.05) YoY, Sales $1.36M Up From $219.59K YoY   Benzinga
04:45PM EDT  Inhibikase Therapeutics Reports Second Quarter 2021 Financial Results and   PR Newswire
Aug 13, 2021
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
Aug 10, 2021
02:42PM EDT  The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs   Benzinga
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 27, 2021
11:13AM EDT  The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts   Benzinga
Jul 26, 2021
10:09AM EDT  Inhibikase To Start Testing Its Parkinson's Candidate In Patients   Benzinga
08:44AM EDT  Inhibikase Therapeutics Says Receives FDA Clearance To Begin Evaluation Of IkT-148009 In Parkingson's Patients   Benzinga
08:44AM EDT  Inhibikase Therapeutics Gets FDA Clearance To Begin Evaluation Of IkT-148009 In Parkinson's Patients   RTTNews
08:43AM EDT  Inhibikase Therapeutics Receives FDA Clearance To Begin Evaluation of   PR Newswire
Jul 20, 2021
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
Jul 15, 2021
09:32AM EDT  JonesTrading Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $12   Benzinga
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
Jul 9, 2021
07:36AM EDT  The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO   Benzinga
Jul 8, 2021
07:45AM EDT  The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test   Benzinga
Jul 1, 2021
08:07AM EDT  The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts   Benzinga
Jun 22, 2021
08:12AM EDT  The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal   Benzinga
Jun 18, 2021
06:45PM EDT  Inhibikase Therapeutics Announces Closing of Follow-On Offering of Common Stock   PR Newswire
07:46AM EDT  The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs   Benzinga
Jun 17, 2021
08:33AM EDT  The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme   Benzinga
Jun 16, 2021
02:32PM EDT  Mid-Afternoon Market Update: Dow Tumbles Over 300 Points; Federal Reserve Maintains Interest Rates   Benzinga
12:03PM EDT  Mid-Day Market Update: Dow Falls 40 Points; Aprea Therapeutics Shares Surge   Benzinga
10:17AM EDT  Mid-Morning Market Update: Markets Mixed; Elanco Animal Health To Acquire Kindred Biosciences   Benzinga
08:20AM EDT  The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO   Benzinga
06:57AM EDT  Inhibikase Therapeutics Stock Drops After Follow-On Equity Offering Of $45M Issued At 26% Discount   Benzinga
05:02AM EDT  44 Biggest Movers From Yesterday   Benzinga
Jun 15, 2021
07:41PM EDT  Inhibikase Therapeutics Prices Follow-On Public Offering of Common Stock   PR Newswire
Jun 14, 2021
02:47PM EDT  Mid-Afternoon Market Update: Dow Tumbles 250 Points; Enochian Biosciences Shares Spike Higher   Benzinga
12:25PM EDT  Mid-Day Market Update: Nasdaq Rises Over 50 Points; Washington Prime Group Shares Plunge   Benzinga
Jun 11, 2021
04:27PM EDT  Inhibikase Therapeutics Inc Files For Offering Of Up To 8M Shares Of Common Stock   Benzinga
May 25, 2021
08:02AM EDT  Inhibikase Therapeutics to Present at Upcoming Jefferies Virtual Healthcare   PR Newswire
May 21, 2021
07:26AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Authorized In Japan, Neovasc's Adverse Ruling In Germany, Metacrine Rallies On Insider Buying   Benzinga
May 20, 2021
08:27AM EDT  The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks   Benzinga
May 18, 2021
07:44AM EDT  The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO   Benzinga
May 17, 2021
04:18PM EDT  Inhibikase Therapeutics Q1 EPS $(0.26) Down From $(0.07) YoY   Benzinga
04:06PM EDT  Inhibikase Therapeutics Reports First Quarter 2021 Financial Results and   PR Newswire
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
Apr 21, 2021
08:01AM EDT  Inhibikase Therapeutics to Present at Sachs 4th Annual Neuroscience Innovation   PR Newswire
07:31AM EDT  The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue   Benzinga
Apr 20, 2021
08:07AM EDT  The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex   Benzinga
Apr 1, 2021
08:08AM EDT  Inhibikase Therapeutics Q4 EPS $(0.15) Down From $(0.05) YoY   Benzinga
08:00AM EDT  Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2020 Financial   PR Newswire
Mar 26, 2021
07:28AM EDT  The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs   Benzinga
Mar 25, 2021
07:58AM EDT  The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut   Benzinga
Mar 4, 2021
08:12AM EST  The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company   Benzinga
Mar 2, 2021
08:05AM EST  Inhibikase Therapeutics to Present at H.C. Wainwright & Co. Global Life   PR Newswire
Feb 22, 2021
08:05AM EST  Inhibikase Therapeutics to Present at the American Society of Experimental   PR Newswire
Feb 17, 2021
12:48PM EST  Inhibikase Initiates Early-Stage Study Of Parkinson's Candidate   Benzinga
10:38AM EST  Shares of micro-cap company Inhibikase Therapeutics, Inc. (IKT) are currently gaining over 10% after the clinical-stage pharmaceutical company announced that first patients were dosed in a phase 1 clinical trial of IkT-148009 to treat Parkinson's disease.   RTTNews
08:27AM EST  Inhibikase Therapeutics Doses First Patients In Phase 1 Trial Of IkT-148009 To Treat Parkinson's Disease   RTTNews
08:06AM EST  Inhibikase Therapeutics Reports First Patients Dosed In Phase 1 Trial Of IkT-148009 To Treat Parkinson's Disease, Related Disorders   Benzinga
08:05AM EST  Inhibikase Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial of IkT-148009 to Treat Parkinson's Disease and Related Disorders   Business Wire
Jan 4, 2021
08:56AM EST  LINTREX To Oversee Trials And Regulatory Issues For Inhibikase's Pipeline Programs Across Multiple Therapeutic Areas   RTTNews
08:11AM EST  Inhibikase Therapeutics Announces Partnership With Clintrex Research Corporation; C. Warren Olanow, MD, To Serve As Interim Chief Medical Officer   Benzinga
08:03AM EST  Corporation; C. Warren Olanow, MD, to Serve as Interim Chief Medical Officer   PR Newswire
Dec 30, 2020
08:16AM EST  The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data   Benzinga
Dec 29, 2020
08:09AM EST  The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica   Benzinga
Dec 28, 2020
10:34AM EST  Inhibikase Therapeutics Announces Closing of Initial Public Offering   PR Newswire
Dec 23, 2020
10:52AM EST  Inhibikase Therapeutics Shares Open For Trade At $10.67; IPO Priced At $10/Share   Benzinga
09:15AM EST  Inhibikase Therapeutics Shares Will Open For Quote At 10:35 a.m. EST, Expected To Open For Trade After 10:45 a.m. EST; IPO Priced At $10/Share   Benzinga
Dec 22, 2020
06:26PM EST  Inhibikase Therapeutics, Inc. Announces Pricing of its Initial Public Offering   PR Newswire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC